The BioMed X Institute
A new research team at XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
RIDGEFIELD, CT / ACCESSWIRE / June 5, 2024 / XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut. This research team's main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently.
The new research team is led by Dr. Lorenzo Talà, Group Leader at XSeed Labs. "Due to insufficient understanding of the mechanisms driving their pathology, therapies to treat fibrotic diseases are limited. The aim of our research group is to develop physiologically relevant in vitro and in silico fibrosis models. By combining both approaches, we will interrogate disease mechanisms, identify drug delivery pathways, and assess drug safety in order to facilitate drug development toward resolving fibrotic tissues."
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "We are pleased that we could successfully translate the innovation model we established in Heidelberg and New Haven to work inside a major pharma research and development campus. We have a long history of successful collaboration with Boehringer Ingelheim at our Heidelberg institute, and we are proud to extend this collaboration to their U.S. headquarters in Ridgefield, Connecticut."
"We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases," said Carine Boustany, PhD, U.S. Research Site Head and Global Head of Immunology and Respiratory Diseases Research, Boehringer Ingelheim. "In parallel, we will harness these innovative disease model systems to assess the safety of novel anti-fibrotic concepts, and identify better ways to deliver our molecules," said Xiaorong He, PhD, U.S. Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim.
"We are excited to start our first XSeed Labs team at Boehringer Ingelheim in Ridgefield. It is the beginning of a unique innovation model that promotes scientific exchange between major players in biomedical research," says Mark Johnston, CEO of BioMed X USA.
About BioMed X and XSeed Labs
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds -- academia and industry -- and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model - called XSeed Labs - entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27
Related Images
SOURCE: BioMed X Institute & XSeed Labs
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Masar Destination Achieves LEED for Communities Gold Certification23.1.2026 21:35:00 CET | Press release
Affirming its Commitment to Sustainability MAKKAH, SAUDI ARABIA / ACCESS Newswire / January 23, 2026 / Masar: a landmark urban development in the heart of Makkah, owned, developed, and operated by Umm Al Qura for Development & Construction Company, has been awarded LEED Gold certification under the LEED for Communities rating system, one of the highest international certifications in sustainability and the built environment. This achievement recognizes Masar's adoption of an integrated approach that places people and the environment at the heart of its design and planning processes. This accomplishment reflects the company's commitment to developing sustainable urban communities in line with global best practices. By balancing quality of life, resource efficiency, and environmental protection, it paves the way for long-term positive impact and a more sustainable future. Commenting on the achievement, Mr. Yasser Abuateek, Chief Executive Officer of Umm Al Qura for Development & Construc
Sir Ivan Releases "Love Is The Piece"23.1.2026 20:45:00 CET | Press release
The Peace Anthem of the 21st Century MIAMI, FLORIDA / ACCESS Newswire / January 23, 2026 / Electronic Dance Music (EDM) recording artist, Sir Ivan, has co-written and recorded a peace song that will stand the test of time. Inspired by 20th-century anti-war rock legends such as John Lennon and Bob Dylan, Sir Ivan's new single, "Love Is The Piece," is a bold reminder to all generations that love remains the only path to peace and is found only in our hearts. Stream/Download On All Platforms "As the son of an Auschwitz survivor (see UnstoppableSiggi.com), my life has been deeply affected by the tragedy of having over 50 family members murdered during the Holocaust, simply because they were Jewish. My father's miraculous survival and my subsequent birth had a purpose. And that purpose was for me to one day write and sing a peace song that would help stop violence, bloodshed, and war between people. That song is ‘Love Is The Piece,'" declared Sir Ivan. While global conflicts and civil unres
From NASA to Your Boardroom: Freelancer Opens 85-Million-Mind Innovation Engine to All Enterprises23.1.2026 14:00:00 CET | Press release
The platform that slashed NASA's R&D costs and compressed three-day computations into one hour is now available to any organisation Previous challenge winner's spacecraft solution is bound for space What do you do when your toughest technical problem stumps every expert in your building? If you're NASA, you throw it open to 85 million minds across 140 countries. Starting today, any company can do the same. SAN FRANCISCO, CA / ACCESS Newswire / January 23, 2026 / Freelancer (ASX:FLN) announced the global launch of its Moonshot Innovation Program, opening the breakthrough platform that has delivered over 20,000 solutions to NASA, NIH, and the CDC to enterprises worldwide. The same system that helped NASA save 80-99% on R&D costs, compressed Bureau of Reclamation river modelling from 72 hours to 60 minutes, and generated 54 genome therapy breakthroughs for NIH is now available to any organization with a problem that traditional consulting can't crack. The results speak louder than any pit
Datavault AI Inc. Completes Acquisition of API Media23.1.2026 12:00:00 CET | Press release
Technology Provider API Media extends Datavault AI and the patented ADIO Technology to the Live Outdoor Event Market PHILADELPHIA, PA / ACCESS Newswire / January 23, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real‑world asset tokenization technologies, today announced that it has closed its previously announced acquisition of API Media Innovation Inc ("API"), a provider of media infrastructure and event technology solutions. API, headquartered in New Jersey, has a decades-long tradition of providing innovative audio and visual technologies to the world of media, sports, and entertainment. API's clients include some of the most prestigious and sought-after sports venues and events, made possible through a dedicated and customer-first culture cultivated over decades. "We are pleased to complete this acquisition, which marks a decisive next step in our strategy to scale Datavault AI's propr
Aviwell Closes €11 Million Series A Investment Round to Scale AI‑Driven Microbiota Platform for Sustainable Animal Nutrition23.1.2026 06:01:00 CET | Press release
TOULOUSE, FRANCE AND BOSTON, MA / ACCESS Newswire / January 23, 2026 / Aviwell SAS, a deep‑tech animal nutrition company headquartered in Toulouse, today announced the successful completion of a €11 million Series A investment round, welcoming three new investors: Blue Revolution Fund (BRF), Blast.Club, and SWEN Capital Partners. The financing will support Aviwell's next phase of growth as the company scales its AI‑driven microbiome discovery and development platform and advances native, nature‑based biological solutions for global agri‑food markets, initially focused on poultry and aquaculture. Built on decades of research pioneered by Aviwell's co‑Founder, Prof. Remy BURCELIN, into how naturally occurring bacterial ecologies administered early in life can have a durable impact on animal growth, health, and resilience, Aviwell has developed Aneto™, an AI‑powered microbiome discovery platform. Aneto™ identifies specific molecular mechanisms - modes of action - that enable the selection
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom